Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy
Roberto Contieri(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Charles C. Guo(The University of Texas MD Anderson Cancer Center), Valentina Grajales(The University of Texas MD Anderson Cancer Center), Graciela M. Nogueras‐González(The University of Texas MD Anderson Cancer Center), Alberto Martini(The University of Texas MD Anderson Cancer Center), Patrick J. Hensley(University of Kentucky), Amanda A. Myers, Kelly K. Bree(The University of Texas MD Anderson Cancer Center), Neema Navai(The University of Texas MD Anderson Cancer Center), Wei Shen Tan, Colin P. Dinney(The University of Texas MD Anderson Cancer Center)
Cited by 7
Related Papers
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines
|European Urology|2023|656
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
|Cancer Discovery|2018|570
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
|The Lancet Oncology|2021|532
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
|Clinical Cancer Research|2015|355